Skip to main content
Premium Trial:

Request an Annual Quote

OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling Test

NEW YORK – OmniSeq said on Tuesday that it has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program for its Insight cancer genomic and immune profiling test.

With the approval, the test, which detects genomic variants, genomic signatures, and immune gene expression to inform cancer treatment decisions, will be available to patients in New York.

OmniSeq will make the test available in the US exclusively through Labcorp and will sell it globally to biopharma companies through Labcorp Drug Development. In Canada, Dynacare, a Labcorp company, will be the exclusive provider of the test. OmniSeq and Labcorp signed an exclusive distribution agreement for OmniSeq's tests in 2017 and expanded it in 2019.

"The launch of OmniSeq Insight represents the continued evolution of OmniSeq’s commitment to innovation and to delivering the most advanced, comprehensive solid tumor profiling assay. It is designed to detect and characterize the genomic and immune features of cancer to quickly guide more precise, individualized treatment decisions for patients with solid tumor cancers," OmniSeq CEO Margot Schoenborn said in a statement.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.